Sugi Predict

Sugi Predict / Compounds / SCHEMBL2266638

SCHEMBL2266638

SCHEMBL2266638

CCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 9/20 1.00
▸ GBA2 Q9HCG7 13/20 0.68
▸ GBA1 P04062 5/20 0.68
▸ MGAM O43451 4/20 0.68
▸ UGCG Q16739 3/20 0.68
▸ SI P14410 3/20 0.68
▸ AGL P35573 2/20 0.68
▸ MEN1 O00255 1/20 0.66
▸ LMNA P02545 1/20 0.66
▸ MAPK1 P28482 1/20 0.66
▸ KMT2A Q03164 1/20 0.66
▸ TDP1 Q9NUW8 1/20 0.66
▸ LCT P09848 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23503369 1.00 GAA (1.00) GAAGBA2GBA1MGAMUGCG
SCHEMBL2268187 1.00 GAA (1.00) GAAGBA2GBA1MGAMUGCG
SCHEMBL23503288 1.00 GAA (1.00) GAAGBA2GBA1MGAMUGCG
SCHEMBL2772479 0.84 GAA (1.00) GAAGBA2GBA1MGAMUGCG
SCHEMBL14020271 0.84 GAA (1.00) GAAGBA2GBA1MGAMUGCG
SCHEMBL6820276 0.84 GAA (1.00) GAAGBA2GBA1MGAMUGCG
SCHEMBL23503370 0.84 GAA (1.00) GAAGBA2GBA1MGAMUGCG
SCHEMBL23503282 0.84 GAA (1.00) GAAGBA2GBA1MGAMUGCG
SCHEMBL6817340 0.84 GAA (1.00) GAAGBA2GBA1MGAMUGCG
SCHEMBL2270637 0.83 GAA (0.70) GAAGBA2GBA1MGAMUGCG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4646931-A9 BIODEGRADABLE IMINOSUGARS AND AMINO CYCLITOL GLYCOSIDES INHIBITING ALPHA-GLUCOSIDASE WITH SYNERGISTIC INSECTICIDE OR ACARICIDE ACTIVITY OR BOTH Francisco Aragon S.L.U (ES) 2025-12-24 — — EP disclosed
EP-4646931-A1 BIODEGRADABLE IMINOSUGARS AND AMINO CYCLITOL GLYCOSIDES INHIBITING ALPHA-GLUCOSIDASE WITH SYNERGISTIC INSECTICIDE OR ACARICIDE ACTIVITY OR BOTH Francisco Aragon S.L.U (ES) 2025-11-12 — — EP disclosed
WO-2024089310-A1 BIODEGRADABLE IMINOSUGARS AND AMINO CYCLITOL GLYCOSIDES INHIBITING ALPHA-GLUCOSIDASE WITH SYNERGISTIC INSECTICIDE OR ACARICIDE ACTIVITY OR BOTH FRANCISCO ARAGÓN S.L.U (ES) 2024-05-02 — — WO disclosed
US-20180221357-A1 METHOD FOR THE TREATMENT OF POMPE DISEASE USING 1-DEOXYNOJIRIMYCIN DERIVATIVES AMICUS THERAPEUTICS, INC. (US) 2018-08-09 — — US disclosed
US-20180221357-A1 METHOD FOR THE TREATMENT OF POMPE DISEASE USING 1-DEOXYNOJIRIMYCIN DERIVATIVES AMICUS THERAPEUTICS, INC. (US) 2018-08-09 — — US disclosed
EP-1896083-B1 A METHOD FOR THE TREATMENT OF POMPE DISEASE USING 1-DEOXYNOJIRIMYCIN AND DERIVATIVES AMICUS THERAPEUTICS INC (US) 2016-03-02 — — EP disclosed
US-9181184-B2 Method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives AMICUS THERAPEUTICS, INC. (US) 2015-11-10 — — US disclosed
US-9181184-B2 Method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives AMICUS THERAPEUTICS, INC. (US) 2015-11-10 — — US disclosed
US-20110195929-A1 COMPOUNDS FOR THE TREATMENT OF FLAVIVIRAL INFECTIONS SUMMIT CORPORATION PLC (GB) 2011-08-11 — — US disclosed
US-7884115-B2 Composition comprising N-butyl-1-deoxy-nojirimycin, D-glucaro-delta-lactam, and N-ethyl-1-dexynojirimycin in a pharmaceutically acceptable carrier; treatment of chronic pain and neurodegeneration, neuropathic pain, visceral pain, fibromyalgia pain, inflammatory pain, headache pain, muscle pain ALLERGAN, INC. (US) 2011-02-08 — — US disclosed
US-7884115-B2 Composition comprising N-butyl-1-deoxy-nojirimycin, D-glucaro-delta-lactam, and N-ethyl-1-dexynojirimycin in a pharmaceutically acceptable carrier; treatment of chronic pain and neurodegeneration, neuropathic pain, visceral pain, fibromyalgia pain, inflammatory pain, headache pain, muscle pain ALLERGAN, INC. (US) 2011-02-08 — — US disclosed
US-20080085920-A1 Compositions Comprising Nb-Dnj, Ne-Dnj Or D-Glucaro-Delta-Lactam And Their Uses For The Treatment Of Pain And Other Neurological Condittions ALLERGAN, INC. 2008-04-10 — — US disclosed
US-20080085920-A1 Compositions Comprising Nb-Dnj, Ne-Dnj Or D-Glucaro-Delta-Lactam And Their Uses For The Treatment Of Pain And Other Neurological Condittions ALLERGAN, INC. 2008-04-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180221357-A1 METHOD FOR THE TREATMENT OF POMPE DISEASE USING 1-DEOXYNOJIRIMYCIN DERIVATIVES GAA, MAN2B1, MAN1B1 GAA 1/4885GBA2 13/4885GBA1 7/4885
US-20110195929-A1 COMPOUNDS FOR THE TREATMENT OF FLAVIVIRAL INFECTIONS GPI, GALE, HAVCR2 GAA 107/4885GBA2 106/4885GBA1 18/4885
US-20080085920-A1 Compositions Comprising Nb-Dnj, Ne-Dnj Or D-Glucaro-Delta-Lactam And Their Uses For The Treatment Of Pain And Other Neurological Condittions NLN, B3GNT2, NRDC GAA 76/4885GBA2 50/4885GBA1 135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.